1
|
Baltogianni M, Giapros V, Dermitzaki N. Recent Challenges in Diagnosis and Treatment of Invasive Candidiasis in Neonates. CHILDREN (BASEL, SWITZERLAND) 2024; 11:1207. [PMID: 39457172 PMCID: PMC11506641 DOI: 10.3390/children11101207] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/13/2024] [Revised: 09/28/2024] [Accepted: 09/29/2024] [Indexed: 10/28/2024]
Abstract
Invasive Candida infections represent a significant cause of morbidity and mortality in the neonatal intensive care unit (NICU), particularly among preterm and low birth weight neonates. The nonspecific clinical presentation of invasive candidiasis, resembling that of bacterial sepsis with multiorgan involvement, makes the diagnosis challenging. Given the atypical clinical presentation and the potential detrimental effects of delayed treatment, empirical treatment is often initiated in cases with high clinical suspicion. This underscores the need to develop alternative laboratory methods other than cultures, which are known to have low sensitivity and a prolonged detection time, to optimize therapeutic strategies. Serum biomarkers, including mannan antigen/anti-mannan antibody and 1,3-β-D-glucan (BDG), both components of the yeast cell wall, a nano-diagnostic method utilizing T2 magnetic resonance, and Candida DNA detection by PCR-based techniques have been investigated as adjuncts to body fluid cultures and have shown promising results in improving diagnostic efficacy and shortening detection time in neonatal populations. This review aims to provide an overview of the diagnostic tools and the current management strategies for invasive candidiasis in neonates. Timely and accurate diagnosis followed by targeted antifungal treatment can significantly improve the survival and outcome of neonates affected by Candida species.
Collapse
Affiliation(s)
| | - Vasileios Giapros
- Neonatal Intensive Care Unit, School of Medicine, University of Ioannina, 45500 Ioannina, Greece; (M.B.); (N.D.)
| | | |
Collapse
|
2
|
Lucini C, Obrová K, Krickl I, Nogueira F, Kocmanová I, Herndlhofer S, Gleixner KV, Sperr WR, Frank T, Andrade N, Peters C, Engstler G, Dworzak M, Attarbaschi A, van Grotel M, van den Heuvel-Eibrink MM, Moiseev IS, Rogacheva Y, Zubarovskaya L, Zubarovskaya N, Pichler H, Lawitschka A, Koller E, Keil F, Mayer J, Weinbergerová B, Valent P, Lion T. Prevalence of fungal DNAemia mediated by putatively non-pathogenic fungi in immunocompromised patients with febrile neutropenia: a prospective cohort study. J Hematol Oncol 2024; 17:63. [PMID: 39113112 PMCID: PMC11304904 DOI: 10.1186/s13045-024-01583-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2024] [Accepted: 07/24/2024] [Indexed: 08/11/2024] Open
Abstract
Invasive fungal disease (IFD) presents a life-threatening condition in immunocompromised patients, thus often prompting empirical administration of antifungal treatment, without adequate mycological evidence. Over the past years, wide use of antifungal prophylaxis resulted in decreased occurrence of IFD but has contributed to changes in the spectrum of fungal pathogens, revealing the occurrence of previously rare fungal genera causing breakthrough infections. The expanding spectrum of clinically relevant fungal pathogens required the implementation of screening approaches permitting broad rather than targeted fungus detection to support timely onset of pre-emptive antifungal treatment. To address this diagnostically important aspect in a prospective setting, we analyzed 935 serial peripheral blood (PB) samples from 195 pediatric and adult patients at high risk for IFD, involving individuals displaying febrile neutropenia during treatment of hematological malignancies or following allogeneic hematopoietic stem cell transplantation. Two different panfungal-PCR-screening methods combined with ensuing fungal genus identification by Sanger sequencing were employed. In the great majority of PB-specimens displaying fungal DNAemia, the findings were transient and revealed fungi commonly regarded as non-pathogenic or rarely pathogenic even in the highly immunocompromised patient setting. Hence, to adequately exploit the diagnostic potential of panfungal-PCR approaches for detecting IFD, particularly if caused by hitherto rarely observed fungal pathogens, it is necessary to confirm the findings by repeated testing and to identify the fungal genus present by ensuing analysis. If applied appropriately, panfungal-PCR-screening can help prevent unnecessary empirical therapy, and conversely, contribute to timely employment of effective pre-emptive antifungal treatment strategies.
Collapse
Affiliation(s)
- Chantal Lucini
- St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria
| | - Klára Obrová
- St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria
| | - Isabella Krickl
- St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria
| | - Filomena Nogueira
- St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria
| | - Iva Kocmanová
- Department of Clinical Microbiology and Immunology, University Hospital Brno, Brno, Czech Republic
| | - Susanne Herndlhofer
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
| | - Karoline V Gleixner
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
- Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria
| | - Wolfgang R Sperr
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
- Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria
| | - Tijana Frank
- St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria
| | - Nuno Andrade
- St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria
| | - Christina Peters
- St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria
- Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
| | - Gernot Engstler
- Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
| | - Michael Dworzak
- St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria
- Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
| | - Andishe Attarbaschi
- St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria
- Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
| | - Martine van Grotel
- Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands
| | - Marry M van den Heuvel-Eibrink
- Princess Máxima Centre for Paediatric Oncology, Utrecht, the Netherlands
- Division of Childhealth, Wilhelmina Childrens Hospital, University of Utrecht, Utrecht, the Netherlands
| | - Ivan S Moiseev
- RM Gorbacheva Children Research Institute, Pavlov University, Saint Petersburg, Russian Federation
| | - Yuliya Rogacheva
- RM Gorbacheva Children Research Institute, Pavlov University, Saint Petersburg, Russian Federation
| | - Ludmilla Zubarovskaya
- RM Gorbacheva Children Research Institute, Pavlov University, Saint Petersburg, Russian Federation
| | - Natalia Zubarovskaya
- Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
| | - Herbert Pichler
- Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
| | - Anita Lawitschka
- St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria
- Department of Pediatrics, St. Anna Children's Hospital, Medical University of Vienna, Vienna, Austria
| | | | - Felix Keil
- Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria
- 3rd Medical Dept, Hanusch Hospital, Vienna, Austria
| | - Jiří Mayer
- Department of Internal Medicine-Haematology and Oncology, University Hospital Brno, Brno, Czech Republic
- Department of Internal Medicine-Haematology and Oncology, Masaryk University, Brno, Czech Republic
| | - Barbora Weinbergerová
- Department of Internal Medicine-Haematology and Oncology, University Hospital Brno, Brno, Czech Republic
- Department of Internal Medicine-Haematology and Oncology, Masaryk University, Brno, Czech Republic
| | - Peter Valent
- Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, Vienna, Austria
- Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria
| | - Thomas Lion
- St. Anna Children's Cancer Research Institute (CCRI), Zimmermannplatz 10, Vienna, A-1090, Austria.
- Ludwig Boltzmann Institute for Hematology and Oncology, Medical University of Vienna, Vienna, Austria.
- Department of Paediatrics, Medical University of Vienna, Vienna, Austria.
| |
Collapse
|
3
|
Misra A, Powell EA. Preanalytical Challenges of Molecular Microbiology Tests. Clin Lab Med 2024; 44:33-43. [PMID: 38280796 DOI: 10.1016/j.cll.2023.10.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2024]
Abstract
As infectious disease diagnostics increasingly incorporates molecular techniques, there are unique preanalytical concerns that must be considered. First, noninvasive specimen types that may be inadequate for culture-based diagnostics may be acceptable when using molecular tests. Second, specimen containers must be evaluated for the presence of substances that may interfere with amplification or sequencing reactions. Finally, the capacity of transport, storage, and processing conditions to maintain nucleic acid integrity and avoid contamination must be assessed. This review explores these issues and the effects they may have on result quality.
Collapse
Affiliation(s)
- Anisha Misra
- Department of Laboratory Medicine, Cleveland Clinic, Robert J. Tomsich Pathology and Laboratory Medicine Institute, 10300 Carnegie Avenue LL-1, Cleveland, OH 44195, USA
| | - Eleanor A Powell
- Department of Pathology and Laboratory Medicine, University of Cincinnati College of Medicine, 3188 Bellevue Avenue, Cincinnati, OH 45219, USA.
| |
Collapse
|